Clinical trial NCT06755489: Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA
Official title: Evaluation of Quality of Life in a Cohort of Diarrhoeic Irritable Bowel Syndrome (IBS-D) Patients Assuming GABA.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diarrhoea Predominant Irritable Bowel Syndrome
Keywords: gamma-aminobutyric acid
diarrhoea
abdominal pain
irritable bowel syndrome
GABA
Lead sponsor: University of Pisa
Sponsor class: OTHER
Collaborators: name: Azienda Ospedaliero-Universitaria Pisana (AOUP)
First posted: 2025-01-01
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Monocentric, randomized, double-blind, parallel group, placebo-controlled, cross-over study
Primary purpose: TREATMENT

Brief summary: The study aims to evaluate the impact on quality of life and abdominal discomfort of GABA and Melissa food supplement administration in patients with diarrhea-predominant irritable bowel syndrome.

Detailed description: Rationale: Visceral pain represents a grievous form of pain that affects about 25% of the world population; abdominal pain is the most common gastrointestinal problem, encountered in a high percentage of adolescents, above all in women (Morales-Soto and Gulbransen, 2018). It can be the result of prolonged inflammatory processes, such as in inflammatory bowel diseases (IBDs), but in many patients, negative diagnostic test results lead to the diagnosis of irritable bowel syndrome (IBS) (Giamberardino et al., 2010).

Abdominal pain is a common manifestation in IBD, due to changes that begin with hypersensitivity of the primary sensory neurons, which innervate the gastrointestinal tract, and afterwards reach the central nervous system (CNS) (Srinath et al., 2012). Inflammation does not seem to completely explain altered perception of pain in patients affect by IBD, as 20%-50% of patients complain about abdominal pain in the clinical remission stage (Minderhoud et al., 2004; Srinath et al., 2012). IBS is a functional bowel disorder characterized by the presence of chronic/recurrent abdominal pain or discomfort, with altered bowel habits and consequent anomalies in stool frequency and form (Portincasa et al., 2017). Pathogenesis of IBS is only partially understood, even though there is some evidence that changes in the digestive motility and secretion, visceral hypersensitivity, abnormalities of enteroendocrine and immune systems, genetic factors, infections, alterations of the intestinal microbiota and inflammation could play a role in this functional disease. (Bellini M et al., 2014). Patients may be categorized as diarrheal-predominant (IBS-D), constipation-predominant IBS-C), or as having both (IBS-M) (Khan et al., 2017)(Lacy BE, 2016). In this context, finding valid therapies that can alleviate chronic visceral pain represents an important medical need to improve patients' quality of life. Unfortunately, the current therapeutics to treat visceral pain offer little benefit for abdominal symptoms and can produce undesired and serious side effects (Catanzaro et al., 2015). In this regard, the pain management remains unsatisfactory, so there is a growing demand for the development of effective treatments. Considering that visceral pain has been related to inflammatory processes (Cervero, 2014), as well as to alterations in the enteric barrier and immune response (Carabotti et al., 2015), a product able to protect the intestinal mucosa by indirectly controlling inflammation and at the same time modulating immune response could be the answer. In this regard, gamma aminobutyric acid (GABA) is known to exert a number of beneficial effects at digestive level. For instance, GABA has a protective role during inflammatory processes by modulating cytokine production (Gros et al., 2021). Moreover, products containing GABA have been proven to strengthen intestinal epithelial barrier and to modulate immune-inflammatory response (Sokovic et al., 2019; Cataldo et al., 2020).

Objectives: Primary: to evaluate the changes in quality of life in IBS-D patients taking GABA food supplement. Secondary: evaluation of changes in abdominal discomfort in IBS-D patients taking GABA food supplement; evaluation of global symptom score in IBS-D patients taking GABA food supplement; self evaluation of psychological impact of IBS-D in patients taking GABA food supplement; intestinal microbiota changes in IBS-D patients taking GABA food supplement; evaluation of epithelial barrier impairment in IBS-D patients taking GABA food supplement; evaluation of systemic inflammation in IBS-D patients taking GABA food supplement.

Investigational product, dose, and mode of administration: Regimen A: EIRENE® (containing GABA and Melissa officials) food supplement table 530 mg, 1 tablet three times a day. Regimen B: placebo (microcrystalline cellulose, rice bran, bitter cocoa powder) table 530 mg, 1 tablet three times a day.

Methodology: This is a monocentric, randomized, double-blind, parallel group, placebo-controlled, 2-period cross-over study investigating the changes in quality of life, abdominal symptoms, intestinal microbiota, intestinal permeability, systemic inflammation in patients taking a GABA-based food supplement. Patients will be evaluated before and after each treatment period (Regimen A and Regimen B) through clinical questionnaires and scales, blood and stool tests.

The following questionnaires will be administered:

* Short-Form 36
* 11 points visual analogue scale for abdominal discomfort
* Hospital Anxiety and Depression Scale
* Bristol Stool Scale

The following evaluations will be performed on blood samples:

* TNF-alfa, IL-1β, C-reactive protein and IL-10 levels to assess systemic inflammation
* Lypopolisaccharide binding protein (LBP) to assess intestinal epithelial barrier impairment.
* Blood tests for safety (glucose, BUN, AST, ALT, bilirubin, ALP, creatinin, blood count and formula, platelets, Na, K, Ca)

The following evaluations will be performed on stool samples:

* Fecal calprotectin
* Fecal microbiome analysis

Inclusion criteria: Age \> 18 years and ≤ 75; a positive diagnosis of IBS-D according to Rome IV criteria; both males and females; negative relevant additional screening or consultation whenever appropriate; colonoscopy if there are alarm symptoms (eg. Rectal bleeding, pseudodiarrhea. If the patients' age is \> or = 50 yrs a colonoscopy within 5 years is mandatory); availability to participate in the clinical study, confirmed by the signed informed consent form; ability to conform to the study protocol; patients' ability to complain study protocol procedures; subjects who decide to use single or double contraceptive methods not to conceive during study period.

Exclusion criteria: patients with IBS-C, IBS-M and IBS-U according to Rome IV criteria; presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant; ascertained intestinal organic diseases, including celiac disease, food allergies or inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis); previous major abdominal surgery; active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable); use of -pre or probiotics, topical and/or systemic antibiotic and prokinetic therapy during the 15 days before treatment starts; systematic/frequent use of contact laxatives; pregnant or breastfeeding woman; females of childbearing potential in the absence of effective contraceptive methods; inability to conform to protocol; treatment with any investigational drug within the previous 30 days; recent history or suspicion of alcohol abuse or drug addiction; presence of red or white flags at the Rome IV Psychosocial Alarm Questionnaire for Functional gastrointestinal Disorders.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years and ≤ 75
* A positive diagnosis of IBS-D according to Rome IV criteria.
* Both males and females.
* Negative relevant additional screening or consultation whenever appropriate
* Colonoscopy if there are alarm symptoms (eg. Rectal bleeding, pseudodiarrhea). If the patients' age is \> or = 50 yrs a colonoscopy within 5 years is mandatory.
* Availability to participate in the clinical study, confirmed by the signed informed consent form.
* Ability to conform to the study protocol.
* Patients' ability to complain study protocol procedures.
* Subjects who decide to use single or double contraceptive methods not to conceive during study period.

Exclusion Criteria:

* Patients with IBS-C, IBS-M and IBS-U according to Rome IV criteria.
* Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant.
* Ascertained intestinal organic diseases, including celiac disease, food allergies or inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis).
* Previous major abdominal surgery.
* Active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment are also acceptable).
* Use of -pre or probiotics, topical and/or systemic antibiotic and prokinetic therapy during the 15 days before treatment starts.
* Systematic/frequent use of contact laxatives.
* Pregnant or breastfeeding woman.
* Females of childbearing potential in the absence of effective contraceptive methods.
* Inability to conform to protocol.
* Treatment with any investigational drug within the previous 30 days.
* Recent history or suspicion of alcohol abuse or drug addiction.
* Presence of red or white flags at the Rome IV Psychosocial Alarm Questionnaire for Functional gastrointestinal Disorders

Primary outcomes:
measure: Quality of life
timeFrame: From enrollment to the end of treatment at 12 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3, FU)
Secondary outcomes:
measure: Abdominal discomfort
timeFrame: From enrollment to the end of treatment at 12 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3, FU)
measure: Psychological impact
timeFrame: From enrollment to the end of treatment at 12 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3, FU)
measure: Intestinal microbiota
timeFrame: From enrollment to the end of treatment at 10 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3)
measure: Epithelial barrier impairment
timeFrame: From enrollment to the end of treatment at 10 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3)
measure: Systemic inflammation
timeFrame: From enrollment to the end of treatment at 10 weeks. Evaluated at every scheduled visit (V0, V1, V2, V3)
Other outcomes:
Locations:
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria Pisana
city: Pisa
country: Italy
facility: University of Pisa
Study officials:
References: